

# Author Index Volume 22 (2010)

The issue number is given in front of the pagination

- Abe, K., see Yang, J. (1) 225–234  
Ábrahám, C.S., see Deli, M.A. (3) 777–794  
Adam, J.-F., see Ancelin, M.-L. (S3) S105–S113  
Adversi, M., see Di Nino, G. (S3) S121–S127  
Agosti, C., see Borroni, B. (1) 195–203  
Agosti, C., see Padovani, A. (3) 923–931  
Ahuja, M., see Mandal, P.K. (S3) S27–S34  
Aisa, B., see Gil-Bea, F.J. (3) 829–838  
Ala, T., see Struble, R.G. (2) 393–399  
Alberici, A., see Borroni, B. (1) 195–203  
Albertini, V., see Ghidoni, R. (3) 985–991  
Alcolea, D., see Samaranch, L. (4) 1065–1071  
Aldudo, J., see Martínez-García, A. (4) 1181–1187  
Alldred, M.J., see Ginsberg, S.D. (2) 631–639  
Almeida, O.F.X., see Liu, J. (2) 541–556  
Alonso, A., see Samaranch, L. (4) 1065–1071  
Alpérovitch, A., see Lamberta, J.-C. (1) 247–255  
Álvarez, S., see Blanco, A. (2) 493–505  
Alvarez, V., see Lamberta, J.-C. (1) 247–255  
Amouyel, P., see Lamberta, J.-C. (1) 247–255  
An, Y., see Thambisetty, M. (4) 1099–1109  
Ancín, I., see Samaranch, L. (4) 1065–1071  
Ancelin, M.-L., G. de Roquefeuil, J. Scali, F. Bonnel, J.-F. Adam, J.-C. Chémin, J.-P. Cristol, A.-M. Dupuy, I. Carrière and K. Ritchie, Long-Term Post-Operative Cognitive Decline in the Elderly: The Effects of Anesthesia Type, Apolipoprotein E Genotype, and Clinical Antecedents (S3) S105–S113  
Andreasson, U., see Chiasserini, D. (4) 1281–1288  
Annoni, G., see Lamberta, J.-C. (1) 247–255  
Antunez, C., see Lamberta, J.-C. (1) 247–255  
Arai, K., see Yoshiyama, Y. (1) 295–306  
Arbel-Ornath, M., M. Becker, P. Rabinovich-Toidman, M. Gartner and B. Solomon, Immunomodulation of A $\beta$ PP Processing Alleviates Amyloid- $\beta$ -Related Pathology in Alzheimer's Disease Transgenic Mice (2) 469–482  
Archetti, S., see Padovani, A. (3) 923–931  
Arenaza-Urquijo, E.M., see Sala-Llonch, R. (2) 523–539  
Arnim, C.A.F.v., see Steinacker, P. (1) 119–128  
Arosio, B., see Lamberta, J.-C. (1) 247–255  
Arrang, J.-M., see Motawaj, M. (3) 861–871  
Astarita, G., see Murphy, M.P. (1) 135–150  
Avila, J., see Gahete, M.D. (3) 819–828  
Avni, S., see Israeli-Korn, S.D. (3) 1005–1013  
Ayala, P., see Subramanian, S. (2) 619–629  
Babiloni, C., R. Lizio, F. Vecchio, G.B. Frisoni, M. Pievani, C. Geroldi, F. Claudia, R. Ferri, B. Lanuzza and P.M. Rossini, Reactivity of Cortical Alpha Rhythms to Eye Opening in Mild Cognitive Impairment and Alzheimer's Disease: an EEG Study (4) 1047–1064  
Bahar-Fuchs, A., G. Chételat, V.L. Villemagne, S. Moss, K. Pike, C.L. Masters, C. Rowe and G. Savage, Olfactory Deficits and Amyloid- $\beta$  Burden in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Aging: A PiB PET Study (4) 1081–1087  
Bajo, R., F. Maestú, A. Nevado, M. Sancho, R. Gutiérrez, P. Campo, N.P. Castellanos, P. Gil, S. Moratti, E. Pereda and F. del-Pozo, Functional Connectivity in Mild Cognitive Impairment During a Memory Task: Implications for the Disconnection Hypothesis (1) 183–193  
Baker, L.D., L.L. Frank, K. Foster-Schubert, P.S. Green, C.W. Wilkinson, A. McTiernan, B.A. Cholerton, S.R. Plymate, M.A. Fishel, G.S. Watson, G.E. Duncan, P.D. Mehta and S. Craft, Aerobic Exercise Improves Cognition for Older Adults with Glucose Intolerance, A Risk Factor for Alzheimer's Disease (2) 569–579  
Baltrons, M.A., see Lichtenstein, M.P. (4) 1135–1155  
Bandy, D., see Tzimopoulou, S. (4) 1241–1256  
Barabash, A., see Samaranch, L. (4) 1065–1071  
Barbeau, E., see Didic, M. (4) 1269–1279

- Barbieri, P., see Nobili, F. (3) 993–1003
- Barcikowska, M., see Gabryelewicz, T. (4) 1123–1133
- Barczak, A., see Gabryelewicz, T. (4) 1123–1133
- Bargalló, N., see Fortea, J. (3) 909–922
- Bargalló, N., see Sala-Llonch, R. (2) 523–539
- Barini, E., see Borghi, R. (3) 771–775
- Barrett, E., see Murphy, M.P. (1) 135–150
- Bartenstein, P., see Förster, S. (2) 581–591
- Bartrés-Faz, D., see Fortea, J. (3) 909–922
- Bartrés-Faz, D., see Sala-Llonch, R. (2) 523–539
- Bartsch, A., see Haller, S. (1) 315–327
- Basun, H., see Sundelöf, J. (4) 1223–1230
- Beach, T.G., see Valla, J. (1) 307–313
- Becker, M., see Arbel-Ornath, M. (2) 469–482
- Becker, R.E., see Winblad, B. (4) 1201–1208
- Beckett, T.L., see Murphy, M.P. (1) 135–150
- Bednar, M.M., see Vanderweyde, T. (S3) S91–S104
- Beecham, G.W., see Lamberta, J.-C. (1) 247–255
- Belden, C.M., see Sabbagh, M.N. (3) 1015–1021
- Belinson, H., Z. Kariv-Inbal, R. Kayed, E. Masliah and D.M. Michaelson, Following Activation of the Amyloid Cascade, Apolipoprotein E4 Drives the *in vivo* Oligomerization of Amyloid- $\beta$  Resulting in Neurodegeneration (3) 959–970
- Bellelli, G., see Padovani, A. (3) 923–931
- Belmar, S., see Ill-Raga, G. (2) 641–652
- Benito-León, J., A.J. Mitchell, S. Vega and F. Bermejo-Pareja, A Population-Based Study of Cognitive Function in Older People with Subjective Memory Complaints (1) 159–170
- Benito-León, J., see Bermejo-Pareja, F. (3) 949–958
- Benito-León, J., see Cacho, J. (3) 889–896
- Bennet, A.M., C.A. Reynolds, M. Gatz, K. Blennow, N.L. Pedersen and J.A. Prince, Pleiotropy in the Presence of Allelic Heterogeneity: Alternative Genetic Models for the Influence of *APOE* on Serum LDL, CSF Amyloid- $\beta_{42}$ , and Dementia (1) 129–134
- Benussi, L., see Ghidoni, R. (3) 985–991
- Berdynski, M., see Gabryelewicz, T. (4) 1123–1133
- Berendse, H.W., see Reesink, F.E. (1) 87–95
- Berg, D., see Maetzler, W. (3) 933–938
- Bermejo-Pareja, F., J. Benito-León, E.D. Louis, R. Trincado, E. Carro, A. Villarejo and A.G. de la Cámara, Risk of Incident Dementia in Drug-Untreated Arterial Hypertension: A Population-Based Study (3) 949–958
- Bermejo-Pareja, F., see Benito-León, J. (1) 159–170
- Bermejo-Pareja, F., see Martínez-García, A. (4) 1181–1187
- Berr, C., see Lamberta, J.-C. (1) 247–255
- Bertram, L., see Lamberta, J.-C. (1) 247–255
- Bettens, K., see Lamberta, J.-C. (1) 247–255
- Beyer, N., see Coulson, D.T.R. (4) 1111–1122
- Bian, J.-S., see Liu, Y.-Y. (4) 1189–1200
- Bigni, B., see Padovani, A. (3) 923–931
- Bilbao, J.M., see Gabryelewicz, T. (4) 1123–1133
- Bilotta, F., A. Doronzio, E. Stazi, L. Titi, V. Fodale, G. Di Nino and G. Rosa, Postoperative Cognitive Dysfunction: Toward the Alzheimer's Disease Pathomechanism Hypothesis (S3) S81–S89
- Binetti, G., see Ghidoni, R. (3) 985–991
- Bird, N.P., see Tzimopoulou, S. (4) 1241–1256
- Black, S.E., see Gabryelewicz, T. (4) 1123–1133
- Blake, J., see Tierney, M.C. (4) 1331–1338
- Blanco, A., S. Álvarez, M. Fresno and M.Á. Muñoz-Fernández, Amyloid- $\beta$  Induces Cyclooxygenase-2 and PGE<sub>2</sub> Release in Human Astrocytes in NF- $\kappa$ B Dependent Manner (2) 493–505
- Blankenstein, M.A., see Mulder, S.D. (4) 1073–1079
- Blankenstein, M.A., see Reesink, F.E. (1) 87–95
- Blennow, K., see Bennet, A.M. (1) 129–134
- Blennow, K., see Chiasserini, D. (4) 1281–1288
- Blennow, K., see Sundelöf, J. (4) 1223–1230
- Blesa, R., see Samaranch, L. (4) 1065–1071
- Blobner, M., see Eckel, B. (S3) S21–S26
- Boada, M., see Lamberta, J.-C. (1) 247–255
- Bonetti, M., see Prestia, A. (4) 1339–1349
- Bonnel, F., see Ancelin, M.-L. (S3) S105–S113
- Bonuccelli, U., see Borroni, B. (1) 195–203
- Borghi, R., A. Piccini, E. Barini, G. Cirmena, M. Guglielmotto, E. Tamagno, M. Fornaro, G. Perry, M.A. Smith, A. Garuti and M. Tabaton, Up-regulation of Presenilin 1 in Brains of Sporadic, Late-Onset Alzheimer's Disease (3) 771–775
- Borro, M., R.A. Cavallaro, G. Gentile, V. Nicolìa, A. Fuso, M. Simmaco and S. Scarpa, One-Carbon Metabolism Alteration Affects Brain Proteome Profile in a Mouse Model of Alzheimer's Disease (4) 1257–1268
- Borroni, B., M. Malinverno, F. Gardoni, M. Grassi, L. Parnetti, C. Agosti, A. Alberici, E. Premi, U. Bonuccelli, R. Gasparotti, P. Calabresi, M. Di Luca and A. Padovani, Combining CSF Tau form Ratio and MRI Midbrain to Pons Measure to Identify Early Progressive Supranuclear Palsy (1) 195–203
- Borroni, B., see Padovani, A. (3) 923–931
- Bosch, B., see Fortea, J. (3) 909–922
- Bosch, B., see Sala-Llonch, R. (2) 523–539
- Bosch-Morató, M., see Ill-Raga, G. (2) 641–652
- Bosco, P., see Lamberta, J.-C. (1) 247–255
- Bossù, P., see Lamberta, J.-C. (1) 247–255

- Boucau, M.-C., see Candela, P. (3) 849–859
- Boulanger, E., see Candela, P. (3) 849–859
- Bredesen, D.E., V. John and V. Galvan, Importance of the Caspase Cleavage Site in Amyloid- $\beta$  Protein Precursor (1) 57–63
- Brewer, G.J., see Parihar, M.S. (3) 741–763
- Brewer, G.J., see Struble, R.G. (2) 393–399
- Brice, A., see Broustal, O. (3) 765–769
- Brockbank, S., see Coulson, D.T.R. (4) 1111–1122
- Brockmann, K., see Maetzler, W. (3) 933–938
- Broustal, O., A. Camuzat, L. Guillot-Noël, N. Guy, S. Millecamps, D. Deffond, L. Lacomblez, V. Golfier, D. Hannequin, F. Salachas, W. Camu, M. Didic, B. Dubois, V. Meininger, I. Le Ber, A. Brice and the French clinical and genetic research network on FTD/FTD-MND, *FUS* Mutations in Frontotemporal Lobar Degeneration with Amyotrophic Lateral Sclerosis (3) 765–769
- Brouwers, N., see Lamberta, J.-C. (1) 247–255
- Brown, A.P., see Tzimopoulou, S. (4) 1241–1256
- Browne, A., see Zhang, C. (2) 683–694
- Bruce-Keller, A.J., see Ebenezer, P.J. (3) 839–848
- Brugnolo, A., see Nobili, F. (3) 993–1003
- Bruinsma, G., see Winblad, B. (4) 1201–1208
- Buerger, K., see Förster, S. (2) 581–591
- Bullido, M.J., see Lamberta, J.-C. (1) 247–255
- Bullido, M.J., see Martínez-García, A. (4) 1181–1187
- Burr, O., see Rosengarten, B. (2) 415–421
- Cabranes, J.A., see Samaranch, L. (4) 1065–1071
- Cacho, J., J. Benito-León, R. García-García, B. Fernández-Calvo, J.L. Vicente-Villardón and A.J. Mitchell, Does the Combination of the MMSE and Clock Drawing Test (Mini-Clock) Improve the Detection of Mild Alzheimer's Disease and Mild Cognitive Impairment? (3) 889–896
- Calabresi, P., see Borroni, B. (1) 195–203
- Calabresi, P., see Chiasserini, D. (4) 1281–1288
- Callebert, J., see Motawaj, M. (3) 861–871
- Campbell, J., see Thambisetty, M. (4) 1099–1109
- Campion, D., see Lamberta, J.-C. (1) 247–255
- Campo, P., see Bajo, R. (1) 183–193
- Camu, W., see Broustal, O. (3) 765–769
- Camuzat, A., see Broustal, O. (3) 765–769
- Candela, P., F. Gosselet, J. Saint-Pol, E. Sevin, M.-C. Boucau, E. Boulanger, R. Cecchelli and L. Fenart, Apical-to-Basolateral Transport of Amyloid- $\beta$  Peptides through Blood-Brain Barrier Cells is Mediated by the Receptor for Advanced Glycation End-Products and is Restricted by P-Glycoprotein (3) 849–859
- Cao, Y., Y. Xiao, R. Ravid and Z.-Z. Guan, Changed Clathrin Regulatory Proteins in the Brains of Alzheimer's Disease Patients and Animal Models (1) 329–342
- Carrière, I., see Ancelin, M.-L. (S3) S105–S113
- Carriba, P., see Lichtenstein, M.P. (4) 1135–1155
- Carro, E., see Bermejo-Pareja, F. (3) 949–958
- Carro, E., see Martínez-García, A. (4) 1181–1187
- Caselli, R.J., see Valla, J. (1) 307–313
- Castañó, J.P., see Gahete, M.D. (3) 819–828
- Castellanos, N.P., see Bajo, R. (1) 183–193
- Castiglia, M., see Tzimopoulou, S. (4) 1241–1256
- Cavallaro, R.A., see Borro, M. (4) 1257–1268
- Ceccaldi, M., see Didic, M. (4) 1269–1279
- Cecchelli, R., see Candela, P. (3) 849–859
- Cedazo-Mínguez, A., see Gil-Bea, F.J. (2) 405–413
- Cedazo-Mínguez, A., see Gil-Bea, F.J. (3) 829–838
- Cerini, C., see Padovani, A. (3) 923–931
- Cerpa, W., see Ill-Raga, G. (2) 641–652
- Cervantes, S., see Samaranch, L. (4) 1065–1071
- Chabriat, H., see Zhu, Y.-C. (2) 663–672
- Chang, L., see Liu, J. (2) 541–556
- Chang, Y.-H., see Na, H.-R. (1) 151–158
- Chauhan, A., see Ji, L. (2) 609–617
- Chauhan, V., see Ji, L. (2) 609–617
- Chauviré, V., see Sarazin, M. (1) 285–294
- Che, S., see Ginsberg, S.D. (2) 631–639
- Cheminal, J.-C., see Ancelin, M.-L. (S3) S105–S113
- Chen, K., see Tzimopoulou, S. (4) 1241–1256
- Chen, S., K. Townsend, T.E. Goldberg, P. Davies and C. Conejero-Goldberg, MAPT Isoforms: Differential Transcriptional Profiles Related to 3R and 4R Splice Variants (4) 1313–1329
- Chen, X., J.F. Wagener, D.H. Morgan, L. Hui, O. Ghribi and J.D. Geiger, Endolysosome Mechanisms Associated with Alzheimer's Disease-like Pathology in Rabbits Ingesting Cholesterol-Enriched Diet (4) 1289–1303
- Chételat, G., see Bahar-Fuchs, A. (4) 1081–1087
- Chiasserini, D., L. Parnetti, U. Andreasson, H. Zetterberg, D. Giannandrea, P. Calabresi and K. Blennow, CSF Levels of Heart Fatty Acid Binding Protein are Altered During Early Phases of Alzheimer's Disease (4) 1281–1288
- Cho, S.-T., see Na, H.-R. (1) 151–158
- Cholerton, B.A., see Baker, L.D. (2) 569–579
- Chupin, M., see Sarazin, M. (1) 285–294
- Cirmena, G., see Borghi, R. (3) 771–775
- Clarimón, J., see Samaranch, L. (4) 1065–1071
- Claudia, F., see Babiloni, C. (4) 1047–1064

- Collette, F., M. Van der Linden and E. Salmon, Dissociation between Controlled and Automatic Processes in the Behavioral Variant of Fronto-Temporal Dementia (3) 897–907
- Colliot, O., see Sarazin, M. (1) 285–294
- Combarros, O., see Lamberta, J.-C. (1) 247–255
- Combarros, O., see Martínez-García, A. (4) 1181–1187
- Conejero-Goldberg, C., see Chen, S. (4) 1313–1329
- Confort-Gouny, S., see Didic, M. (4) 1269–1279
- Connor, D.J., see Sabbagh, M.N. (3) 1015–1021
- Cooper, A., see Westman, E. (1) 171–181
- Córdoba-Chacón, J., see Gahete, M.D. (3) 819–828
- Corneveaux, J.J., see Valla, J. (1) 307–313
- Cosseddu, M., see Padovani, A. (3) 923–931
- Coto, E., see Lamberta, J.-C. (1) 247–255
- Coulson, D.T.R., N. Beyer, J.G. Quinn, S. Brockbank, J. Hellemans, G.B. Irvine, R. Ravid and J.A. Johnston, *BACE1* mRNA Expression in Alzheimer's Disease Postmortem Brain Tissue (4) 1111–1122
- Counts, S.E., see Ginsberg, S.D. (2) 631–639
- Cozzone, P., see Didic, M. (4) 1269–1279
- Craft, S., see Baker, L.D. (2) 569–579
- Cristol, J.-P., see Ancelin, M.-L. (S3) S105–S113
- Csete, M., see Deli, M.A. (3) 777–794
- Csiszár, B., see Deli, M.A. (3) 777–794
- Cumming, P., see Förster, S. (2) 581–591
- Cunningham, V.J., see Tzimopoulou, S. (4) 1241–1256
- Curth, A., see Mutter, J. (2) 357–374
- Cutler, R.G., see Liu, D. (2) 443–457
- Czyzewski, K., see Gabryelewicz, T. (4) 1123–1133
- Dangour, A.D., P.J. Whitehouse, K. Rafferty, S.A. Mitchell, L. Smith, S. Hawkesworth and B. Vellas, B-Vitamins and Fatty Acids in the Prevention and Treatment of Alzheimer's Disease and Dementia: A Systematic Review (1) 205–224
- Dannhardt, V., see Rosengarten, B. (2) 415–421
- Dartigues, J.-F., see Lamberta, J.-C. (1) 247–255
- Dasuri, K., see Ebenezer, P.J. (3) 839–848
- Davies, P., see Chen, S. (4) 1313–1329
- Davis, K., see Sabbagh, M.N. (3) 1015–1021
- De Deyn, P., see Lamberta, J.-C. (1) 247–255
- de Gracia Blanco, M., see Garre-Olmo, J. (4) 1157–1167
- de Gracia Blanco, M., see Garre-Olmo, J. (4) 1169–1180
- de la Cámara, A.G., see Bermejo-Pareja, F. (3) 949–958
- de Roquefeuil, G., see Ancelin, M.-L. (S3) S105–S113
- de Souza, L.C., see Sarazin, M. (1) 285–294
- de Waal, R.M.W., see Timmer, N.M. (2) 345–355
- de Yébenes, J.G., see Mena, M.Á. (S3) S43–S48
- Deffond, D., see Broustal, O. (3) 765–769
- Degerman-Gunnarsson, M., see Sundelöf, J. (4) 1223–1230
- Dekel, B.G.S., see Di Nino, G. (S3) S121–S127
- DeKosky, S.T., see Lamberta, J.-C. (1) 247–255
- del Carmen Mugueta, M., see Gil-Bea, F.J. (3) 829–838
- Del Zompo, M., see Lamberta, J.-C. (1) 247–255
- Delepine, M., see Lamberta, J.-C. (1) 247–255
- Deli, M.A., S. Veszélka, B. Csiszár, A. Tóth, Á. Kittel, M. Csete, Á. Sipos, A. Szalai, L. Fülöp, B. Penke, C.S. Ábrahám and M. Niwa, Protection of the Blood-Brain Barrier by Pentosan Against Amyloid- $\beta$ -Induced Toxicity (3) 777–794
- del-Pozo, F., see Bajo, R. (1) 183–193
- Desenzani, S., see Ghidoni, R. (3) 985–991
- Dessi, B., see Nobili, F. (3) 993–1003
- Deth, R., see Mutter, J. (2) 357–374
- Di Luca, M., see Borroni, B. (1) 195–203
- Di Nino, G., M. Adversi, B.G.S. Dekel, V. Fodale, G. Rosa and R.M. Melotti, Peri-Operative Risk Management in Patients with Alzheimer's Disease (S3) S121–S127
- Di Nino, G., see Bilotta, F. (S3) S81–S89
- Di Nino, G., see Schifilliti, D. (S3) S35–S41
- Didic, M., J.-P. Ranjeva, E. Barbeau, S. Confort-Gouny, Y. Le Fur, O. Felician, J. Mancini, M. Poncet, M. Ceccaldi and P. Cozzone, Impaired Visual Recognition Memory in Amnesic Mild Cognitive Impairment is Associated with Mesiotemporal Metabolic Changes on Magnetic Resonance Spectroscopic Imaging (4) 1269–1279
- Didic, M., see Broustal, O. (3) 765–769
- Ding, D., see Zhou, B. (2) 673–682
- Ding, K., see Lu, Q. (1) 235–245
- Diniz, B.S., A.L. Teixeira, E.B. Ojopi, L.L. Talib, V.A. Mendonça, W.F. Gattaz and O.V. Forlenza, Higher Serum sTNFR1 Level Predicts Conversion from Mild Cognitive Impairment to Alzheimer's Disease (4) 1305–1311
- DiVito, J.R., see Zhang, C. (2) 683–694
- Dixon, I.J., see Tzimopoulou, S. (4) 1241–1256
- Dong, Y., see Zhang, C. (2) 683–694
- Doronzo, A., see Bilotta, F. (S3) S81–S89
- Double, K.L., see Schofield, E.C. (3) 981–984
- Dowling, A.L.S., see Murphy, M.P. (1) 135–150
- Drago, V., see Prestia, A. (4) 1339–1349
- Du, X.-Y., see Yang, S.-G. (1) 107–117
- Dubois, B., see Broustal, O. (3) 765–769
- Dubois, B., see Sarazin, M. (1) 285–294
- Dufouil, C., see Zhu, Y.-C. (2) 663–672
- Duncan, G.E., see Baker, L.D. (2) 569–579

- Dupuy, A.-M., see Ancelin, M.-L. (S3) S105–S113
- Ebenezer, P.J., A.M. Weidner, H. LeVine, III, W.R. Markesbery, M.P. Murphy, L. Zhang, K. Dasuri, S.O. Fernandez-Kim, A.J. Bruce-Keller, E. Gavilán and J.N. Keller, Neuron Specific Toxicity of Oligomeric Amyloid- $\beta$ : Role for JUN-Kinase and Oxidative Stress (3) 839–848
- Eckel, B., M. Blobner and G. Rammes, Anesthetics Promoting *in vitro* A $\beta$ PP Metabolism and Amyloid- $\beta$  Toxicity (S3) S21–S26
- Eikelenboom, P., see Richard, E. (3) 811–818
- Eling, P., see Haldenwanger, A. (3) 971–980
- Ellis, G., E. Fang, M. Maheshwari, E. Roltsch, L. Holcomb, D. Zimmer, D. Martinez and I.V.J. Murray, Lipid Oxidation and Modification of Amyloid- $\beta$  (A $\beta$ ) *in vitro* and *in vivo* (2) 593–607
- Emanuele, E., see Ghidoni, R. (3) 985–991
- Emch, J., see Haller, S. (1) 315–327
- Engelborghs, S., see Lamberta, J.-C. (1) 247–255
- Epelbaum, J., see Lamberta, J.-C. (1) 247–255
- Erb, M., see Saur, R. (1) 267–284
- Eriksdotter-Jönhagen, M., see Sundelöf, J. (4) 1223–1230
- Eschweiler, G.W., see Saur, R. (1) 267–284
- Fagan, T., see Landhuis, E. (3) 1033–1037
- Fang, E., see Ellis, G. (2) 593–607
- Farrer, L.A., see Israeli-Korn, S.D. (3) 1005–1013
- Felician, O., see Didic, M. (4) 1269–1279
- Felipo, V., see Monfort, P. (3) 795–809
- Fenart, L., see Candela, P. (3) 849–859
- Feng, Y., see Yang, S.-G. (1) 107–117
- Fernández-Calvo, B., see Cacho, J. (3) 889–896
- Fernandez-Kim, S.O., see Ebenezer, P.J. (3) 839–848
- Ferri, R., see Babiloni, C. (4) 1047–1064
- Ferri, R., see Lamberta, J.-C. (1) 247–255
- Ferrucci, L., see Thambisetty, M. (4) 1099–1109
- Fiévet, N., see Lamberta, J.-C. (1) 247–255
- Fishel, M.A., see Baker, L.D. (2) 569–579
- Foa, L., see Vincent, A.J. (3) 699–714
- Fodale, V., K. Ritchie, L.S. Rasmussen and P.K. Mandal, Preface: Anesthetics and Alzheimer's Disease: Background and Research (S3) S1–S3
- Fodale, V., see Bilotta, F. (S3) S81–S89
- Fodale, V., see Di Nino, G. (S3) S121–S127
- Fodale, V., see Mandal, P.K. (S3) S135–S136
- Fodale, V., see Schifilliti, D. (S3) S35–S41
- Forlenza, O.V., see Diniz, B.S. (4) 1305–1311
- Forman, S.A., see Vanderweyde, T. (S3) S91–S104
- Fornaro, M., see Borghi, R. (3) 771–775
- Förster, S., A. Vaitl, S.J. Teipel, I. Yakushev, M. Mustafa, C. la Fougère, A. Rominger, P. Cumming, P. Bartenstein, H. Hampel, T. Hummel, K. Buerger, W. Hundt and S. Steinbach, Functional Representation of Olfactory Impairment in Early Alzheimer's Disease (2) 581–591
- Fortea, J., R. Sala-Llonch, D. Bartrés-Faz, B. Bosch, A. Lladó, N. Bargalló, J.L. Molinuevo and R. Sánchez-Valle, Increased Cortical Thickness and Caudate Volume Precede Atrophy in *PSEN* Mutation Carriers (3) 909–922
- Forti, P., see Lamberta, J.-C. (1) 247–255
- Foster-Schubert, K., see Baker, L.D. (2) 569–579
- Foy, C., see Westman, E. (1) 171–181
- Frank, A., see Martínez-García, A. (4) 1181–1187
- Frank, L.L., see Baker, L.D. (2) 569–579
- Frank-Garcia, A., see Lamberta, J.-C. (1) 247–255
- Fraser, T., see Tayler, H. (4) 1363–1373
- Fresno, M., see Blanco, A. (2) 493–505
- Friedhoff, L.T., see Winblad, B. (4) 1201–1208
- Friedland, R.P., see Israeli-Korn, S.D. (3) 1005–1013
- Frisardi, V., F. Panza, D. Seripa, B.P. Imbimbo, G. Vendemiale, A. Pilotto and V. Solfrizzi, Nutritional Properties of Mediterranean Diet and Cognitive Decline: Possible Underlying Mechanisms (3) 715–740
- Frisoni, G.B., see Babiloni, C. (4) 1047–1064
- Frisoni, G.B., see Prestia, A. (4) 1339–1349
- Frölich, L., see Winblad, B. (4) 1201–1208
- Frommann, I., see Popp, J. (2) 459–468
- Frosch, M.P., see Lu, Q. (1) 235–245
- Frost, S., R.N. Martins and Y. Kanagasagam, Biomarkers for Early Detection of Alzheimer's Disease (1) 1–16
- Fukushima, M., see Zhou, B. (2) 673–682
- Fülöp, L., see Deli, M.A. (3) 777–794
- Funder, K.S., J. Steinmetz and L.S. Rasmussen, Anesthesia for the Patient with Dementia (S3) S129–S134
- Furukawa, K., see Liu, D. (2) 443–457
- Fuso, A., see Borro, M. (4) 1257–1268
- Fuso, A., see Milagre, I. (4) 1209–1221
- Gabryelewicz, T., M. Masellis, M. Berdyski, J.M. Bilbao, E. Rogaeva, P. St. George-Hyslop, A. Barczak, K. Czyzewski, M. Barcikowska, Z. Wszolek, S.E. Black and C. Zekanowski, Intra-Familial Clinical Heterogeneity due to FTL-DU with TDP-43 Proteinopathy Caused by a Novel Deletion in Progranulin Gene (*PGRN*) (4) 1123–1133

- Gahete, M.D., A. Rubio, J. Córdoba-Chacón, F. Gracia-Navarro, R.D. Kineman, J. Avila, R.M. Luque and J.P. Castaño, Expression of the Ghrelin and Neurotensin Systems is Altered in the Temporal Lobe of Alzheimer's Disease Patients (3) 819–828
- Galea, E., see Lichtenstein, M.P. (4) 1135–1155
- Galimberti, D., see Lamberta, J.-C. (1) 247–255
- Galvan, V., see Bredesen, D.E. (1) 57–63
- Gama, M.J., see Milagre, I. (4) 1209–1221
- Gao, X., see Liu, J. (2) 541–556
- García, A., see Lichtenstein, M.P. (4) 1135–1155
- García-García, R., see Cacho, J. (3) 889–896
- Gardoni, F., see Borroni, B. (1) 195–203
- Garnero, L., see Sarazin, M. (1) 285–294
- Garre-Olmo, J., S. López-Pousa, J. Vilalta-Franch, M. de Gracia Blanco and A.B. Vilarrasa, Grouping and Trajectories of Neuropsychiatric Symptoms in Patients with Alzheimer's Disease. Part II: Two-Year Patient Trajectories (4) 1169–1180
- Garre-Olmo, J., S. López-Pousa, J. Vilalta-Franch, M. de Gracia Blanco and A.B. Vilarrasa, Grouping and Trajectories of the Neuropsychiatric Symptoms in Patients with Alzheimer's Disease, Part I: Symptom Clusters (4) 1157–1167
- Gartner, M., see Arbel-Ornath, M. (2) 469–482
- Garuti, A., see Borghi, R. (3) 771–775
- Gasparotti, R., see Borroni, B. (1) 195–203
- Gasparini, R., see Vincent, A.J. (3) 699–714
- Gasser, T., see Maetzler, W. (3) 933–938
- Gattaz, W.F., see Diniz, B.S. (4) 1305–1311
- Gatz, M., see Bennet, A.M. (1) 129–134
- Gavilán, E., see Ebenezer, P.J. (3) 839–848
- Geiger, J.D., see Chen, X. (4) 1289–1303
- Gentile, G., see Borro, M. (4) 1257–1268
- George-Hyslop, P.St., see Gabryelewicz, T. (4) 1123–1133
- Gerardin, E., see Sarazin, M. (1) 285–294
- Geroldi, C., see Babiloni, C. (4) 1047–1064
- Ghidoni, R., L. Benussi, M. Glionna, S. Desenzani, V. Albertini, E. Levy, E. Emanuele and G. Binetti, Plasma Cystatin C and Risk of Developing Alzheimer's Disease in Subjects with Mild Cognitive Impairment (3) 985–991
- Ghribi, O., see Chen, X. (4) 1289–1303
- Giacobini, E., see Winblad, B. (4) 1201–1208
- Giannakopoulos, P., see Haller, S. (1) 315–327
- Giannandrea, D., see Chiasserini, D. (4) 1281–1288
- Giedraitis, V., see Lamberta, J.-C. (1) 247–255
- Giedraitis, V., see Sundelöf, J. (4) 1223–1230
- Gil, P., see Bajo, R. (1) 183–193
- Gil-Bea, F.J., B. Aisa, A. Solomon, M. Solas, M. del Carmen Mugueta, B. Winblad, M. Kivipelto, A. Cedazo-Mínguez and M.J. Ramírez, HPA Axis Dysregulation Associated to Apolipoprotein E4 Genotype in Alzheimer's Disease (3) 829–838
- Gil-Bea, F.J., M. Solas, A. Solomon, C. Mugueta, B. Winblad, M. Kivipelto, M.J. Ramirez and A. Cedazo-Mínguez, Insulin Levels are Decreased in the Cerebrospinal Fluid of Women with Prodromal Alzheimer's Disease (2) 405–413
- Ginsberg, S.D., E.J. Mufson, S.E. Counts, J. Wu, M.J. Alldred, R.A. Nixon and S. Che, Regional Selectivity of rab5 and rab7 Protein Upregulation in Mild Cognitive Impairment and Alzheimer's Disease (2) 631–639
- Girtler, N., see Nobili, F. (3) 993–1003
- Glionna, M., see Ghidoni, R. (3) 985–991
- Godoy, J., see Ill-Raga, G. (2) 641–652
- Gold, G., see Haller, S. (1) 315–327
- Gold, M., see Tzimopoulou, S. (4) 1241–1256
- Goldberg, T.E., see Chen, S. (4) 1313–1329
- Golfier, V., see Broustal, O. (3) 765–769
- Gómez-Isla, T., see Samaranch, L. (4) 1065–1071
- Gong, C.-X., see Run, X. (S3) S49–S55
- González-Pérez, A., see Lamberta, J.-C. (1) 247–255
- Gosselet, F., see Candela, P. (3) 849–859
- Gracia-Navarro, F., see Gahete, M.D. (3) 819–828
- Grassi, M., see Borroni, B. (1) 195–203
- Green, P.S., see Baker, L.D. (2) 569–579
- Greig, N.H., see Liu, D. (2) 443–457
- Greig, N.H., see Winblad, B. (4) 1201–1208
- Grodd, W., see Saur, R. (1) 267–284
- Gu, Y., J.A. Luchsinger, Y. Stern and N. Scarmeas, Mediterranean Diet, Inflammatory and Metabolic Biomarkers, and Risk of Alzheimer's Disease (2) 483–492
- Guan, Z.-Z., see Cao, Y. (1) 329–342
- Guglielmotto, M., see Borghi, R. (3) 771–775
- Guillot-Noël, L., see Broustal, O. (3) 765–769
- Guix, F.X., see Ill-Raga, G. (2) 641–652
- Guo, Q., see Zhou, B. (2) 673–682
- Gutiérrez, R., see Bajo, R. (1) 183–193
- Guy, N., see Broustal, O. (3) 765–769
- Hack, C.E., see Mulder, S.D. (4) 1073–1079
- Haines, J.L., see Lamberta, J.-C. (1) 247–255
- Haldenwanger, A., P. Eling, A. Kastrup and H. Hildebrandt, Correlation between Cognitive Impairment and CSF Biomarkers in Amnesic MCI, non-Amnesic MCI, and Alzheimer's Disease (3) 971–980

- Haller, S., D. Nguyen, C. Rodriguez, J. Emch, G. Gold, A. Bartsch, K.O. Lovblad and P. Giannakopoulos, Individual Prediction of Cognitive Decline in Mild Cognitive Impairment Using Support Vector Machine-Based Analysis of Diffusion Tensor Imaging Data (1) 315–327
- Hallett, W.A., see Tzimopoulou, S. (4) 1241–1256
- Halliday, G.M., see Schofield, E.C. (3) 981–984
- Hampel, H., see Förster, S. (2) 581–591
- Hampel, H., see Teipel, S.J. (2) 507–522
- Han, G., see Kim, H.Y. (1) 73–85
- Han, I.-W., see Na, H.-R. (1) 151–158
- Hannequin, D., see Broustal, O. (3) 765–769
- Hannequin, D., see Lamberta, J.-C. (1) 247–255
- Hänninen, T., see Paajanen, T. (4) 1089–1097
- Hanon, O., see Lamberta, J.-C. (1) 247–255
- Hansson, O., see Sundelöf, J. (4) 1223–1230
- Harris, C.J., see Subramanian, S. (2) 619–629
- Hauser, A.-K., see Maetzler, W. (3) 933–938
- Hawkesworth, S., see Dangour, A.D. (1) 205–224
- Head, E., see Murphy, M.P. (1) 135–150
- Heikkilä, K., see Virta, J.J. (3) 939–948
- Helisalmi, S., see Lamberta, J.-C. (1) 247–255
- Hellems, J., see Coulson, D.T.R. (4) 1111–1122
- Hildebrandt, H., see Haldenwanger, A. (3) 971–980
- Hiltunen, M., see Lamberta, J.-C. (1) 247–255
- Ho, L., see Wang, J. (2) 653–661
- Hodges, J.R. see Schofield, E.C. (3) 981–984
- Holcomb, L., see Ellis, G. (2) 593–607
- Hong, H.-S., J.-Y. Hwang, S.-M. Son, Y.-H. Kim, M. Moon and M.-J. Inhee, FK506 Reduces Amyloid Plaque Burden and Induces MMP-9 in A $\beta$ PP/PS1 Double Transgenic Mice (1) 97–105
- Hong, Z., see Zhou, B. (2) 673–682
- Hooper, N.M., see Whitehouse, I.J. (3) 1023–1031
- Hoozemans, J.J.M., see Richard, E. (3) 811–818
- Hsu, W.-M., see Kapoor, A. (2) 423–442
- Huang, W.-D., see Yu, C.-J. (1) 257–266
- Huentelman, M.J., see Valla, J. (1) 307–313
- Hugonot-Diener, L., see Sarazin, M. (1) 285–294
- Hui, L., see Chen, X. (4) 1289–1303
- Hummel, T., see Förster, S. (2) 581–591
- Hundt, W., see Förster, S. (2) 581–591
- Hwang, J.-Y., see Hong, H.-S. (1) 97–105
- Hwang, S.-A., see Na, H.-R. (1) 151–158
- Hye, A., see Thambisetty, M. (4) 1099–1109
- Ill-Raga, G., E. Ramos-Fernández, F.X. Guix, M. Tajés, M. Bosch-Morató, E. Palomer, J. Godoy, S. Belmar, W. Cerpa, J.W. Simpkins, N.C. Inestrosa and F.J. Muñoz, Amyloid- $\beta$  Peptide Fibrils Induce Nitro-Oxidative Stress in Neuronal Cells (2) 641–652
- Imbimbo, B.P., see Frisardi, V. (3) 715–740
- Imbimbo, B.P., see Ross, J.S. (2) 401–404
- Inestrosa, N.C., see Ill-Raga, G. (2) 641–652
- Ingelsson, M., see Lamberta, J.-C. (1) 247–255
- Ingelsson, M., see Sundelöf, J. (4) 1223–1230
- Inhee, M.-J., see Hong, H.-S. (1) 97–105
- Inzelberg, R., see Israeli-Korn, S.D. (3) 1005–1013
- Inzhutova, A.I., see Salmina, A.B. (1) 17–36
- Irvine, G.B., see Coulson, D.T.R. (4) 1111–1122
- Ishikawa, C., see Yoshiyama, Y. (1) 295–306
- Israeli-Korn, S.D., M. Massarwa, E. Schechtman, R. Strugatsky, S. Avni, L.A. Farrer, R.P. Friedland and R. Inzelberg, Mild Cognitive Impairment is Associated with Mild Parkinsonian Signs in a Door-to-Door Study (3) 1005–1013
- Jackson, C., see Whitehouse, I.J. (3) 1023–1031
- Jacobson, S., see Sabbagh, M.N. (3) 1015–1021
- Järvenpää, T., see Virta, J.J. (3) 939–948
- Jesse, S., see Steinacker, P. (1) 119–128
- Jessen, F., see Popp, J. (2) 459–468
- Jeter, B., see Tzimopoulou, S. (4) 1241–1256
- Ji, L., V. Chauhan, P. Mehta, J. Wegiel, S. Mehta and A. Chauhan, Relationship Between Proteolytically Cleaved Gelsolin and Levels of Amyloid- $\beta$  Protein in the Brains of Down Syndrome Subjects (2) 609–617
- Jiang, H., see Liu, D. (2) 443–457
- John, V., see Bredesen, D.E. (1) 57–63
- Johnston, J.A., see Coulson, D.T.R. (4) 1111–1122
- Jones, S., see Lu, Q. (1) 235–245
- Junqué, C., see Sala-Llonch, R. (2) 523–539
- Jyoti, A., A. Plano, G. Riedel and B. Platt, EEG, Activity, and Sleep Architecture in a Transgenic A $\beta$ PP<sup>swe</sup>/PSEN1<sup>A246E</sup> Alzheimer's Disease Mouse (3) 873–887
- Kaji, K., see Tokita, Y. (4) 1351–1361
- Kamboh, M.I., see Lamberta, J.-C. (1) 247–255
- Kanagasalingam, Y., see Frost, S. (1) 1–16
- Kapoor, A., W.-M. Hsu, B.-J. Wang, G.-H. Wu, T.-Y. Lin, S.-J. Lee, C.-T. Yen, S.-M. Liang and Y.-F. Liao, Caveolin-1 Regulates  $\gamma$ -Secretase-Mediated A $\beta$ PP Processing by Modulating Spatial Distribution of  $\gamma$ -Secretase in Membrane (2) 423–442
- Kaprio, J., see Virta, J.J. (3) 939–948
- Kariv-Inbal, Z., see Belinson, H. (3) 959–970
- Kastrup, A., see Haldenwanger, A. (3) 971–980
- Kataria, R., see Sabbagh, M.N. (3) 1015–1021
- Kayed, R., see Belinson, H. (3) 959–970
- Kehoe, P.G., see Tayler, H. (4) 1363–1373

- Keller, J.N., see Ebenezer, P.J. (3) 839–848  
 Kilander, L., see Sundelöf, J. (4) 1223–1230  
 Kim, D.J., see Kim, H.Y. (1) 73–85  
 Kim, H.Y., Y. Kim, G. Han and D.J. Kim, Regulation of *in vitro* A $\beta$ <sub>1–40</sub> Aggregation Mediated by Small Molecules (1) 73–85  
 Kim, S.-Y., see Na, H.-R. (1) 151–158  
 Kim, T.-Y., see Na, H.-R. (1) 151–158  
 Kim, Y., see Kim, H.Y. (1) 73–85  
 Kim, Y.-H., see Hong, H.-S. (1) 97–105  
 Kineman, R.D., see Gahete, M.D. (3) 819–828  
 Kinkingnéhun, S., see Sarazin, M. (1) 285–294  
 Kinsey, A., see Thambisetty, M. (4) 1099–1109  
 Kittel, Á., see Deli, M.A. (3) 777–794  
 Kivipelto, M., see Gil-Bea, F.J. (2) 405–413  
 Kivipelto, M., see Gil-Bea, F.J. (3) 829–838  
 Klafki, H., see Steinacker, P. (1) 119–128  
 Klein, M., see Reesink, F.E. (1) 87–95  
 Kohyama, K., see Tokita, Y. (4) 1351–1361  
 Kojima, A., see Yoshiyama, Y. (1) 295–306  
 Kölsch, H., see Popp, J. (2) 459–468  
 Kornhuber, J., see Popp, J. (2) 459–468  
 Koskenvuo, M., see Virta, J.J. (3) 939–948  
 Kretschmar, H.A., see Steinacker, P. (1) 119–128  
 Kryscio, R.J., see Murphy, M.P. (1) 135–150  
 Ksiazak-Reding, H., see Wang, J. (2) 653–661  
 Kuang, C.-X., see Yu, C.-J. (1) 257–266  
 Kuiperij, H.B., see Timmer, N.M. (2) 345–355  
 Kusne, Y., see Valla, J. (1) 307–313  
 Kwok, J., see Schofield, E.C. (3) 981–984
- la Fougère, C., see Förster, S. (2) 581–591  
 Lacomblez, L., see Broustal, O. (3) 765–769  
 Lahiri, D.K., see Liu, D. (2) 443–457  
 Lai, R.Y.K., see Tzimopoulou, S. (4) 1241–1256  
 Lamberta, J.-C., K. Slegers, A. González-Pérez, M. Ingelsson, G.W. Beecham, M. Hiltunen, O. Combarros, M.J. Bullido, N. Brouwers, K. Bettens, C. Berr, F. Pasquier, F. Richard, S.T. DeKosky, D. Hannequin, J.L. Haines, G. Tognoni, N. Fiévet, J.-F. Dartigues, C. Tzourio, S. Engelborghs, B. Arosio, E. Coto, P. De Deyn, M. Del Zompo, I. Mateo, M. Boada, C. Antunez, J. Lopez-Arrieta, J. Epelbaum, B.-M.M. Schjeide, A. Frank-Garcia, V. Giedraitis, S. Helisalmi, E. Porcellini, A. Pilotto, P. Forti, R. Ferri, M. Delepine, D. Zelenika, M. Lathrop, E. Scarpini, G. Siciliano, V. Solfrizzi, S. Sorbi, G. Spalletta, G. Ravaglia, F. Valdivieso, S. Vepsäläinen, V. Alvarez, P. Bosco, M. Mancuso, F. Panza, B. Nacmias, P. Bossù, O. Hanon, P. Piccardi, G. Annoni, D. Mann, P. Marambaud, D. Seripa, D. Galimberti, R.E. Tanzi, L. Bertram, C. Lendon, L. Lannfelt, F. Licastro, D. Campion, M.A. Pericak-Vance, H. Soininen, C. Van Broeckhoven, A. Alperovitch, A. Ruiz, M.I. Kamboh and P. Amouyel, The *CALHMI* P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: A Meta-Analysis Study (1) 247–255  
 Lamet, I., see Samaranch, L. (4) 1065–1071  
 Landhuis, E. and T. Fagan, Meeting Report: Trial News: Woes, New Approaches (3) 1033–1037  
 Lanford, G.W., see Lu, Q. (1) 235–245  
 Lannfelt, L., see Lamberta, J.-C. (1) 247–255  
 Lannfelt, L., see Sundelöf, J. (4) 1223–1230  
 Lanuzza, B., see Babiloni, C. (4) 1047–1064  
 Larsson, A., see Sundelöf, J. (4) 1223–1230  
 Lathrop, M., see Lamberta, J.-C. (1) 247–255  
 Le Ber, I., see Broustal, O. (3) 765–769  
 Le Fur, Y., see Didic, M. (4) 1269–1279  
 Lee, J.-H., see Liu, D. (2) 443–457  
 Lee, S.-J., see Kapoor, A. (2) 423–442  
 Lehericy, S., see Sarazin, M. (1) 285–294  
 Lehnert, S., see Steinacker, P. (1) 119–128  
 Lemstra, A.W., see Reesink, F.E. (1) 87–95  
 Lendon, C., see Lamberta, J.-C. (1) 247–255  
 LeVine, III, H., see Ebenezer, P.J. (3) 839–848  
 LeVine, III, H., see Murphy, M.P. (1) 135–150  
 Levy, E., see Ghidoni, R. (3) 985–991  
 Lewczuk, P., see Popp, J. (2) 459–468  
 Leyhe, T., see Saur, R. (1) 267–284  
 Liang, S.-M., see Kapoor, A. (2) 423–442  
 Liang, Z., see Run, X. (S3) S49–S55  
 Liao, Y.-F., see Kapoor, A. (2) 423–442  
 Licastro, F., see Lamberta, J.-C. (1) 247–255  
 Lichtenstein, M.P., P. Carriba, M.A. Baltrons, B. Wojciak-Stothard, J.R. Peterson, A. García and E. Galea, Secretase-Independent and RhoGTPase/PAK/ERK-Dependent Regulation of Cytoskeleton Dynamics in Astrocytes by NSAIDs and Derivatives (4) 1135–1155  
 Lin, T.-Y., see Kapoor, A. (2) 423–442  
 Lin, Y., see Murphy, M.P. (1) 135–150  
 Ling, T.-J., see Yang, S.-G. (1) 107–117  
 Liu, D., M. Pitta, J.-H. Lee, B. Ray, D.K. Lahiri, K. Furukawa, M. Mughal, H. Jiang, J. Villarreal, R.G. Cutler, N.H. Greig and M.P. Mattson, The *K<sub>ATP</sub>* Channel Activator Diazoxide Ameliorates Amyloid- $\beta$  and Tau Pathologies and Improves Memory in the 3xTgAD Mouse Model of Alzheimer's Disease (2) 443–457



- Liu, J., L. Chang, F. Roselli, O.F.X. Almeida, X. Gao, X. Wang, D.T. Yew and Y. Wu, Amyloid- $\beta$  Induces Caspase-Dependent Loss of PSD-95 and Synaptophysin Through NMDA Receptors (2) 541–556
- Liu, R.-T., see Yang, S.-G. (1) 107–117
- Liu, Y.-Y. and J.-S. Bian, Hydrogen Sulfide Protects Amyloid- $\beta$  Induced Cell Toxicity in Microglia (4) 1189–1200
- Lizio, R., see Babiloni, C. (4) 1047–1064
- Lladó, A., see Fortea, J. (3) 909–922
- Lleó, A., see Samaranch, L. (4) 1065–1071
- Lopez-Arrieta, J., see Lambert, J.-C. (1) 247–255
- López-Pousa, S., see Garre-Olmo, J. (4) 1157–1167
- López-Pousa, S., see Garre-Olmo, J. (4) 1169–1180
- Lorenzo, E., see Samaranch, L. (4) 1065–1071
- Lotay, N., see Tzimopoulou, S. (4) 1241–1256
- Louis, E.D., see Bermejo-Pareja, F. (3) 949–958
- Lovblad, K.O., see Haller, S. (1) 315–327
- Love, S., see Tayler, H. (4) 1363–1373
- Lovestone, S., see Paajanen, T. (4) 1089–1097
- Lovestone, S., see Thambisetty, M. (4) 1099–1109
- Lovestone, S., see Westman, E. (1) 171–181
- Loy, C., see Schofield, E.C. (3) 981–984
- Lu, J., see Tokita, Y. (4) 1351–1361
- Lu, Q., K. Ding, M.P. Frosch, S. Jones, M. Wolfe, W. Xia and G.W. Lanford, Alzheimer's Disease-Linked Presenilin Mutation (*PS1M146L*) Induces Filamin Expression and  $\gamma$ -Secretase Independent Redistribution (1) 235–245
- Luchsinger, J.A., see Gu, Y. (2) 483–492
- Luque, R.M., see Gahete, M.D. (3) 819–828
- Lynham, S., see Thambisetty, M. (4) 1099–1109
- Maestú, F., see Bajo, R. (1) 183–193
- Maetzler, W., V. Stoycheva, B. Schmid, C. Schulte, A.-K. Hauser, K. Brockmann, A. Melms, T. Gasser and D. Berg, Neprilysin Activity in Cerebrospinal Fluid is Associated with Dementia and Amyloid- $\beta_{42}$  Levels in Lewy Body Disease (3) 933–938
- Maheshwari, M., see Ellis, G. (2) 593–607
- Maier, W., see Popp, J. (2) 459–468
- Malek-Ahmadi, M., see Sabbagh, M.N. (3) 1015–1021
- Malinovskaya, N.A., see Salmina, A.B. (1) 17–36
- Malinverno, M., see Borroni, B. (1) 195–203
- Mancini, J., see Didic, M. (4) 1269–1279
- Mancuso, M., see Lambert, J.-C. (1) 247–255
- Mandal, P.K. and M. Ahuja, Comprehensive Nuclear Magnetic Resonance Studies on Interactions of Amyloid- $\beta$  with Different Molecular Sized Anesthetics (S3) S27–S34
- Mandal, P.K. and V. Fodale, Editorial (S3) S135–S136
- Mandal, P.K., see Fodale, V. (S3) S1–S3
- Mandal, P.K., see Schifilliti, D. (S3) S35–S41
- Mann, D., see Lambert, J.-C. (1) 247–255
- Manson, J., see Tierney, M.C. (4) 1331–1338
- Marambaud, P., see Lambert, J.-C. (1) 247–255
- Marcos, A., see Samaranch, L. (4) 1065–1071
- Markesbery, W.R., see Ebenezer, P.J. (3) 839–848
- Martinez, D., see Ellis, G. (2) 593–607
- Martínez-García, A., I. Sastre, M. Recuero, J. Aldudo, E. Vilella, I. Mateo, P. Sánchez-Juan, T. Vargas, E. Carro, F. Bermejo-Pareja, E. Rodríguez-Rodríguez, O. Combarros, M. Rosich-Estrago, A. Frank, F. Valdivieso and M.J. Bullido, *PLA2G3*, a Gene Involved in Oxidative Stress Induced Death, is Associated with Alzheimer's Disease (4) 1181–1187
- Martínez-Lage, P., see Samaranch, L. (4) 1065–1071
- Martins, R.N., see Frost, S. (1) 1–16
- Masellis, M., see Gabryelewicz, T. (4) 1123–1133
- Masliyah, E., see Belinson, H. (3) 959–970
- Mason, S.E., A. Noel-Storr and C.W. Ritchie, The Impact of General and Regional Anesthesia on the Incidence of Post-Operative Cognitive Dysfunction and Post-Operative Delirium: A Systematic Review with Meta-Analysis (S3) S67–S79
- Massarwa, M., see Israeli-Korn, S.D. (3) 1005–1013
- Masters, C.L., see Bahar-Fuchs, A. (4) 1081–1087
- Mateo, I., see Lambert, J.-C. (1) 247–255
- Mateo, I., see Martínez-García, A. (4) 1181–1187
- Matsumoto, Y., see Tokita, Y. (4) 1351–1361
- Matthews, J.C., see Tzimopoulou, S. (4) 1241–1256
- Matthews, P.M., see Tzimopoulou, S. (4) 1241–1256
- Mattson, M.P., see Liu, D. (2) 443–457
- Mazoyer, B., see Zhu, Y.-C. (2) 663–672
- Mazzei, D., see Nobili, F. (3) 993–1003
- McDowell, I., see Tierney, M.C. (4) 1231–1240
- McTiernan, A., see Baker, L.D. (2) 569–579
- Mecocci, P., see Paajanen, T. (4) 1089–1097
- Mehta, P., see Ji, L. (2) 609–617
- Mehta, P.D., see Baker, L.D. (2) 569–579
- Mehta, S., see Ji, L. (2) 609–617
- Mehta, Y. and R. Singh, Cognitive Dysfunction after Cardiac Surgery (S3) S115–S120
- Meininger, V., see Broustal, O. (3) 765–769
- Melms, A., see Maetzler, W. (3) 933–938
- Melotti, R.M., see Di Nino, G. (S3) S121–S127
- Mena, M.Á., J. Perucho, I. Rubio and J.G. de Yébenes, Studies in Animal Models of the Effects of Anesthetics on Behavior, Biochemistry, and Neuronal Cell Death (S3) S43–S48

- Mendonça, V.A., see Diniz, B.S. (4) 1305–1311
- Michaelson, D.M., see Belinson, H. (3) 959–970
- Milagre, I., M.J. Nunes, M. Moutinho, I. Rivera, A. Fuso, S. Scarpa, M.J. Gama and E. Rodrigues, Chromatin-Modifying Agents Increase Transcription of *CYP46A1*, a Key Player in Brain Cholesterol Elimination (4) 1209–1221
- Milian, M., see Saur, R. (1) 267–284
- Millecamps, S., see Broustal, O. (3) 765–769
- Miners, J.S., see Tayler, H. (4) 1363–1373
- Minthon, L., see Sundelöf, J. (4) 1223–1230
- Mistry, P., see Tzimopoulou, S. (4) 1241–1256
- Mitchell, A.J., see Benito-León, J. (1) 159–170
- Mitchell, A.J., see Cacho, J. (3) 889–896
- Mitchell, S.A., see Dangour, A.D. (1) 205–224
- Moineddin, R., see Tierney, M.C. (4) 1231–1240
- Moineddin, R., see Tierney, M.C. (4) 1331–1338
- Molinuevo, J.L., see Fortea, J. (3) 909–922
- Molinuevo, J.-L., see Sala-Llonch, R. (2) 523–539
- Monfort, P. and V. Felipo, Amyloid- $\beta$  Impairs, and Ibuprofen Restores, the cGMP Pathway, Synaptic Expression of AMPA Receptors and Long-Term Potentiation in the Hippocampus (3) 795–809
- Moon, M., see Hong, H.-S. (1) 97–105
- Morales, J., see Murphy, M.P. (1) 135–150
- Moratti, S., see Bajo, R. (1) 183–193
- Morbelli, S., see Nobili, F. (3) 993–1003
- Morgan, D.H., see Chen, X. (4) 1289–1303
- Morra, A., see Tierney, M.C. (4) 1331–1338
- Moss, S., see Bahar-Fuchs, A. (4) 1081–1087
- Motawaj, M., K. Peoc'h, J. Callebert and J.-M. Arrang, CSF Levels of the Histamine Metabolite *tele*-Methylhistamine are only Slightly Decreased in Alzheimer's Disease (3) 861–871
- Moutinho, M., see Milagre, I. (4) 1209–1221
- Mufson, E.J., see Ginsberg, S.D. (2) 631–639
- Mughal, M., see Liu, D. (2) 443–457
- Mugueta, C., see Gil-Bea, F.J. (2) 405–413
- Mulder, S.D., C.E. Hack, W.M. van der Flier, P. Scheltens, M.A. Blankenstein and R. Veerhuis, Evaluation of Intrathecal Serum Amyloid P (SAP) and C-Reactive Protein (CRP) Synthesis in Alzheimer's Disease with the Use of Index Values (4) 1073–1079
- Muñoz, F.J., see Ill-Raga, G. (2) 641–652
- Muñoz-Fernández, M.Á., see Blanco, A. (2) 493–505
- Murphy, D., see Westman, E. (1) 171–181
- Murphy, M.P., J. Morales, T.L. Beckett, G. Astarita, D. Piomelli, A. Weidner, C.M. Studzinski, A.L.S. Dowling, X. Wang, H. LeVine, III, R.J. Kryscio, Y. Lin, E. Barrett and E. Head, Changes in Cognition and Amyloid- $\beta$  Processing with Long Term Cholesterol Reduction using Atorvastatin in Aged Dogs (1) 135–150
- Murphy, M.P., see Ebenezer, P.J. (3) 839–848
- Murray, I.V.J., see Ellis, G. (2) 593–607
- Mustafa, M., see Förster, S. (2) 581–591
- Mutter, J., A. Curth, J. Naumann, R. Deth and H. Walach, Does Inorganic Mercury Play a Role in Alzheimer's Disease? A Systematic Review and an Integrated Molecular Mechanism (2) 357–374
- Na, H.-R., S.-Y. Kim, Y.-H. Chang, M.-H. Park, S.-T. Cho, I.-W. Han, T.-Y. Kim and S.-A. Hwang, Functional Assessment Staging (FAST) in Korean Patients with Alzheimer's Disease (1) 151–158
- Nacmias, B., see Lamberta, J.-C. (1) 247–255
- Naumann, J., see Mutter, J. (2) 357–374
- Nevado, A., see Bajo, R. (1) 183–193
- Nguyen, D., see Haller, S. (1) 315–327
- Nichols, T.E., see Tzimopoulou, S. (4) 1241–1256
- Nicolia, V., see Borro, M. (4) 1257–1268
- Niwa, M., see Deli, M.A. (3) 777–794
- Nixon, R.A., see Ginsberg, S.D. (2) 631–639
- Nobili, F., D. Mazzei, B. Dessi, S. Morbelli, A. Brugnolo, P. Barbieri, N. Girtler, G. Sambuceti, G. Rodriguez and M. Pagani, Unawareness of Memory Deficit in Amnesic MCI: FDG-PET Findings (3) 993–1003
- Noel-Storr, A., see Mason, S.E. (S3) S67–S69
- Nunes, A.F., see Viana, R.J.S. (2) 557–568
- Nunes, M.J., see Milagre, I. (4) 1209–1221
- Oechsner, M., see Rosengarten, B. (2) 415–421
- Offner, H., see Subramanian, S. (2) 619–629
- Ogasa, T., see Yang, J. (1) 225–234
- Ohta, Y., see Yang, J. (1) 225–234
- Ojopi, E.B., see Diniz, B.S. (4) 1305–1311
- Okura, Y., see Tokita, Y. (4) 1351–1361
- Ono, K., see Wang, J. (2) 653–661
- Otto, M., see Steinacker, P. (1) 119–128
- Paajanen, T., T. Hänninen, C. Tunnard, P. Mecocci, T. Sobow, M. Tsolaki, B. Vellas, S. Lovestone and H. Soininen for the AddNeuroMed Consortium, CERAD Neuropsychological Battery Total Score in Multinational Mild Cognitive Impairment and Control Populations: The AddNeuroMed Study (4) 1089–1097
- Pabst, A., see Steinacker, P. (1) 119–128
- Padovani, A., M. Cosseddu, E. Premi, S. Archetti, A. Papetti, C. Agosti, B. Bigni, C. Cerini, B. Paghera, G. Bellelli and B. Borroni, The Speech and Language *FOXP2* Gene Modulates the Phenotype of Frontotemporal Lobar Degeneration (3) 923–931

- Padovani, A., see Borroni, B. (1) 195–203
- Pagani, M., see Nobili, F. (3) 993–1003
- Paghera, B., see Padovani, A. (3) 923–931
- Palomer, E., see Ill-Raga, G. (2) 641–652
- Panza, F., see Frisardi, V. (3) 715–740
- Panza, F., see Lamberta, J.-C. (1) 247–255
- Papetti, A., see Padovani, A. (3) 923–931
- Parihar, M.S. and G.J. Brewer, Amyloid- $\beta$  as a Modulator of Synaptic Plasticity (3) 741–763
- Park, M.-H., see Na, H.-R. (1) 151–158
- Parnetti, L., see Borroni, B. (1) 195–203
- Parnetti, L., see Chiasserini, D. (4) 1281–1288
- Pasinetti, G.M., see Wang, J. (2) 653–661
- Pasquier, F., see Lamberta, J.-C. (1) 247–255
- Pastor, P., see Samaranch, L. (4) 1065–1071
- Patrylo, P.R., see Struble, R.G. (2) 393–399
- Pearson, C., see Sabbagh, M.N. (3) 1015–1021
- Pedersen, N.L., see Bennet, A.M. (1) 129–134
- Penke, B., see Deli, M.A. (3) 777–794
- Peoc'h, K., see Motawaj, M. (3) 861–871
- Pereda, E., see Bajo, R. (1) 183–193
- Pericak-Vance, M.A., see Lamberta, J.-C. (1) 247–255
- Perola, M., see Virta, J.J. (3) 939–948
- Perry, G., see Borghi, R. (3) 771–775
- Perucho, J., see Mena, M.Á. (S3) S43–S48
- Peterson, J.R., see Lichtenstein, M.P. (4) 1135–1155
- Petrova, M.M., see Salmina, A.B. (1) 17–36
- Piccardi, P., see Lamberta, J.-C. (1) 247–255
- Piccini, A., see Borghi, R. (3) 771–775
- Pievani, M., see Babiloni, C. (4) 1047–1064
- Pike, K., see Bahar-Fuchs, A. (4) 1081–1087
- Pilotto, A., see Frisardi, V. (3) 715–740
- Pilotto, A., see Lamberta, J.-C. (1) 247–255
- Piomelli, D., see Murphy, M.P. (1) 135–150
- Pitta, M., see Liu, D. (2) 443–457
- Plano, A., see Jyoti, A. (3) 873–887
- Platt, B., see Jyoti, A. (3) 873–887
- Plymate, S.R., see Baker, L.D. (2) 569–579
- Pöhler, M., see Rosengarten, B. (2) 415–421
- Poncet, M., see Didic, M. (4) 1269–1279
- Popp, J., P. Lewczuk, I. Frommann, H. Kölsch, J. Kornhuber, W. Maier and F. Jessen, Cerebrospinal Fluid Markers for Alzheimer's Disease over the Lifespan: Effects of Age and the APOE $\epsilon$ 4 Genotype (2) 459–468
- Poppe, M., see Westman, E. (1) 171–181
- Porcellini, E., see Lamberta, J.-C. (1) 247–255
- Premi, E., see Borroni, B. (1) 195–203
- Premi, E., see Padovani, A. (3) 923–931
- Prestia, A., V. Drago, P.E. Rasser, M. Bonetti, P.M. Thompson and G.B. Frisoni, Cortical Changes in Incipient Alzheimer's Disease (4) 1339–1349
- Prince, J.A., see Bennet, A.M. (1) 129–134
- Quinn, J.F., see Subramanian, S. (2) 619–629
- Quinn, J.G., see Coulson, D.T.R. (4) 1111–1122
- Rabiner, E.A., see Tzimopoulou, S. (4) 1241–1256
- Rabinovich-Toidman, P., see Arbel-Ornath, M. (2) 469–482
- Rafferty, K., see Dangour, A.D. (1) 205–224
- Räihä, I., see Virta, J.J. (3) 939–948
- Ramalho, R.M., see Viana, R.J.S. (2) 557–568
- Rami, L., see Sala-Llonch, R. (2) 523–539
- Ramirez, M.J., see Gil-Bea, F.J. (2) 405–413
- Ramírez, M.J., see Gil-Bea, F.J. (3) 829–838
- Rammes, G., see Eckel, B. (S3) S21–S26
- Ramos-Fernández, E., see Ill-Raga, G. (2) 641–652
- Ranjeva, J.-P., see Didic, M. (4) 1269–1279
- Rasmussen, L.S. see Fodale, V. (S3) S1–S3
- Rasmussen, L.S., see Funder, K.S. (S3) S129–S134
- Rasser, P.E., see Prestia, A. (4) 1339–1349
- Ravaglia, G., see Lamberta, J.-C. (1) 247–255
- Ravid, R., see Cao, Y. (1) 329–342
- Ravid, R., see Coulson, D.T.R. (4) 1111–1122
- Ray, B., see Liu, D. (2) 443–457
- Recuero, M., see Martínez-García, A. (4) 1181–1187
- Reesink, F.E., A.W. Lemstra, K.D. van Dijk, H.W. Berendse, W.D.J. van de Berg, M. Klein, M.A. Blankenstein, P. Scheltens, M.M. Verbeek and W.M. van der Flier, CSF  $\alpha$ -Synuclein Does Not Discriminate Dementia with Lewy Bodies from Alzheimer's Disease (1) 87–95
- Reiman, E.M., see Tzimopoulou, S. (4) 1241–1256
- Reiman, E.M., see Valla, J. (1) 307–313
- Reiser, M.F., see Teipel, S.J. (2) 507–522
- Resnick, S.M., see Thambisetty, M. (4) 1099–1109
- Reuter, I., see Rosengarten, B. (2) 415–421
- Reynolds, C.A., see Bennet, A.M. (1) 129–134
- Richard, E., W.A. van Gool, J.J.M. Hoozemans, E.S. van Haastert, P. Eikelenboom, A.J.M. Rozemuller and W.D.J. van de Berg, Morphometric Changes in the Cortical Microvascular Network in Alzheimer's Disease (3) 811–818
- Richard, F., see Lamberta, J.-C. (1) 247–255
- Riddoch-Contreras, J., see Thambisetty, M. (4) 1099–1109
- Riedel, G., see Jyoti, A. (3) 873–887
- Rinne, J.O., see Virta, J.J. (3) 939–948
- Ritchie, C.W., see Mason, S.E. (S3) S67–S69
- Ritchie, K., see Ancelin, M.-L. (S3) S105–S113
- Ritchie, K., see Fodale, V. (S3) S1–S3
- Rivera, I., see Milagre, I. (4) 1209–1221

- Rodrigues, C.M.P., see Viana, R.J.S. (2) 557–568  
 Rodrigues, E., see Milagre, I. (4) 1209–1221  
 Rodriguez, C., see Haller, S. (1) 315–327  
 Rodriguez, G., see Nobili, F. (3) 993–1003  
 Rodríguez-Rodríguez, E., see Martínez-García, A. (4) 1181–1187  
 Rogaeva, E., see Gabryelewicz, T. (4) 1123–1133  
 Roher, A.E., see Valla, J. (1) 307–313  
 Roltsch, E., see Ellis, G. (2) 593–607  
 Romano, D., see Zhang, C. (2) 683–694  
 Rominger, A., see Förster, S. (2) 581–591  
 Rosa, G., see Bilotta, F. (S3) S81–S89  
 Rosa, G., see Di Nino, G. (S3) S121–S127  
 Rosa, G., see Schifilliti, D. (S3) S35–S41  
 Roselli, F., see Liu, J. (2) 541–556  
 Rosengarten, B., V. Dannhardt, O. Burr, M. Pöhler, S. Rosengarten, M. Oechsner and I. Reuter, Neurovascular Coupling in Parkinson's Disease Patients: Effects of Dementia and Acetylcholinesterase Inhibitor Treatment (2) 415–421  
 Rosengarten, S., see Rosengarten, B. (2) 415–421  
 Rosich-Estrago, M., see Martínez-García, A. (4) 1181–1187  
 Ross, J.S. and B.P. Imbimbo, Are  $\gamma$ -secretase inhibitors detrimental for Alzheimer's disease patients? (2) 401–404  
 Rossini, P.M., see Babiloni, C. (4) 1047–1064  
 Rowe, C., see Bahar-Fuchs, A. (4) 1081–1087  
 Rozemuller, A.J.M., see Richard, E. (3) 811–818  
 Rubio, A., see Gahete, M.D. (3) 819–828  
 Rubio, I., see Mena, M.Á. (S3) S43–S48  
 Ruiz, A., see Lamberta, J.-C. (1) 247–255  
 Run, X., Z. Liang and C.-X. Gong, Anesthetics and Tau Protein: Animal Model Studies (S3) S49–S55  
 Sabbagh, M.N., M. Malek-Ahmadi, R. Kataria, C.M. Belden, D.J. Connor, C. Pearson, S. Jacobson, K. Davis, R. Yaari and U. Singh, The Alzheimer's Questionnaire: A Proof of Concept Study for a New Informant-Based Dementia Assessment (3) 1015–1021  
 Saint-Pol, J., see Candela, P. (3) 849–859  
 Salachas, F., see Broustal, O. (3) 765–769  
 Sala-Llonch, R., B. Bosch, E.M. Arenaza-Urquijo, L. Rami, N. Bargalló, C. Junqué, J.-L. Molinuevo and D. Bartrés-Faz, Greater Default-Mode Network Abnormalities Compared to High Order Visual Processing Systems in Amnesic Mild Cognitive Impairment: An Integrated Multi-Modal MRI Study (2) 523–539  
 Sala-Llonch, R., see Fortea, J. (3) 909–922  
 Salmina, A.B., A.I. Inzhutova, N.A. Malinovskaya and M.M. Petrova, Endothelial Dysfunction and Repair in Alzheimer-Type Neurodegeneration: Neuronal and Glial Control (1) 17–36  
 Salmon, E., see Collette, F. (3) 897–907  
 Samaranch, L., S. Cervantes, A. Barabash, A. Alonso, J.A. Cabranes, I. Lamet, I. Ancín, E. Lorenzo, P. Martínez-Lage, A. Marcos, J. Clarimón, D. Alcolea, A. Lleó, R. Blesa, T. Gómez-Isla and P. Pastor, The Effect of *MAPT* H1 and *APOE*  $\epsilon$ 4 on Transition from Mild Cognitive Impairment to Dementia (4) 1065–1071  
 Sambuceti, G., see Nobili, F. (3) 993–1003  
 Sánchez-Juan, P., see Martínez-García, A. (4) 1181–1187  
 Sánchez-Valle, R., see Fortea, J. (3) 909–922  
 Sancho, M., see Bajo, R. (1) 183–193  
 Santa-Maria, I., see Wang, J. (2) 653–661  
 Santamaria, L.B., see Schifilliti, D. (S3) S35–S41  
 Sarazin, M., V. Chauviré, E. Gerardin, O. Colliot, S. Kinkingnéhun, L.C. de Souza, L. Hugonot-Diener, L. Garnero, S. Lehericy, M. Chupin and B. Dubois, The Amnesic Syndrome of Hippocampal in Alzheimer's Disease: An MRI Study (1) 285–294  
 Sastre, I., see Martínez-García, A. (4) 1181–1187  
 Saur, R., M. Milian, M. Erb, G.W. Eschweiler, W. Grodd and T. Leyhe, Cortical Activation during Clock Reading as a Quadratic Function of Dementia State (1) 267–284  
 Savage, G., see Bahar-Fuchs, A. (4) 1081–1087  
 Scali, J., see Ancelin, M.-L. (S3) S105–S113  
 Scarneas, N., see Gu, Y. (2) 483–492  
 Scarpa, S., see Borro, M. (4) 1257–1268  
 Scarpa, S., see Milagre, I. (4) 1209–1221  
 Scarpini, E., see Lamberta, J.-C. (1) 247–255  
 Schechtman, E., see Israeli-Korn, S.D. (3) 1005–1013  
 Scheltens, P., see Mulder, S.D. (4) 1073–1079  
 Scheltens, P., see Reesink, F.E. (1) 87–95  
 Schifilliti, D., L.B. Santamaria, G. Rosa, G. Di Nino, P.K. Mandal and V. Fodale, Cholinergic Central System, Alzheimer's Disease, and Anesthetics Liaison: A Vicious Circle? (S3) S35–S41  
 Schjeide, B.-M.M., see Lamberta, J.-C. (1) 247–255  
 Schmid, B., see Maetzler, W. (3) 933–938  
 Schofield, E.C., G.M. Halliday, J. Kwok, C. Loy, K.L. Double and J.R. Hodges, Low Serum Progranulin Predicts the Presence of Mutations: A Prospective Study (3) 981–984  
 Schulte, C., see Maetzler, W. (3) 933–938  
 Searle, G., see Tzimopoulou, S. (4) 1241–1256

- Seripa, D., see Frisardi, V. (3) 715–740
- Seripa, D., see Lamberta, J.-C. (1) 247–255
- Sevin, E., see Candela, P. (3) 849–859
- Siciliano, G., see Lamberta, J.-C. (1) 247–255
- Simmaco, M., see Borro, M. (4) 1257–1268
- Simmons, A., see Westman, E. (1) 171–181
- Simpkins, J.W., see Ill-Raga, G. (2) 641–652
- Singh, R., see Mehta, Y. (S3) S115–S120
- Singh, U., see Sabbagh, M.N. (3) 1015–1021
- Sipos, Á., see Deli, M.A. (3) 777–794
- Sleegers, K., see Lamberta, J.-C. (1) 247–255
- Small, D.H., see Vincent, A.J. (3) 699–714
- Smith, L., see Dangour, A.D. (1) 205–224
- Smith, M.A., see Borghi, R. (3) 771–775
- Sobow, T., see Paajanen, T. (4) 1089–1097
- Soininen for the AddNeuroMed Consortium, H., see Paajanen, T. (4) 1089–1097
- Soininen, H., see Lamberta, J.-C. (1) 247–255
- Sojkova, J., see Thambisetty, M. (4) 1099–1109
- Solas, M., see Gil-Bea, F.J. (2) 405–413
- Solas, M., see Gil-Bea, F.J. (3) 829–838
- Solfrizzi, V., see Frisardi, V. (3) 715–740
- Solfrizzi, V., see Lamberta, J.-C. (1) 247–255
- Solomon, A., see Gil-Bea, F.J. (2) 405–413
- Solomon, A., see Gil-Bea, F.J. (3) 829–838
- Solomon, B., see Arbel-Ornath, M. (2) 469–482
- Son, S.-M., see Hong, H.-S. (1) 97–105
- Sorbi, S., see Lamberta, J.-C. (1) 247–255
- Soumaré, A., see Zhu, Y.-C. (2) 663–672
- Spalletta, G., see Lamberta, J.-C. (1) 247–255
- Spenger, C., see Westman, E. (1) 171–181
- Stazi, E., see Bilotta, F. (S3) S81–S89
- Steer, C.J., see Viana, R.J.S. (2) 557–568
- Steinacker, P., H. Klafki, S. Lehnert, S. Jesse, C.A.F.v. Arnim, H. Tumani, A. Pabst, H.A. Kretzschmar, J. Wiltfang and M. Otto, ERK2 is Increased in Cerebrospinal Fluid of Creutzfeldt-Jakob Disease Patients (1) 119–128
- Steinbach, S., see Förster, S. (2) 581–591
- Steinmetz, J., see Funder, K.S. (S3) S129–S134
- Stern, Y., see Gu, Y. (2) 483–492
- Stevenson, J.A., see Zhang, C. (2) 683–694
- Stoycheva, V., see Maetzler, W. (3) 933–938
- Struble, R.G., T. Ala, P.R. Patrylo, G.J. Brewer and X.-X. Yan, Is Brain Amyloid Production a Cause or a Result of Dementia of The Alzheimer's Type? (2) 393–399
- Strugatsky, R., see Israeli-Korn, S.D. (3) 1005–1013
- Studzinski, C.M., see Murphy, M.P. (1) 135–150
- Subramanian, S., P. Ayala, T.L. Wadsworth, C.J. Harris, A.A. Vandenbark, J.F. Quinn and H. Offner, CCR6: A Biomarker for Alzheimer's-like Disease in a Triple Transgenic Mouse Model (2) 619–629
- Sun, X.-S., see Yang, S.-G. (1) 107–117
- Sundelöf, J., J. Sundström, O. Hansson, M. Eriksdotter-Jönhagen, V. Giedraitis, A. Larsson, M. Degerman-Gunnarsson, M. Ingelsson, L. Minthon, K. Blennow, L. Kilander, H. Basun and L. Lannfelt, Higher Cathepsin B Levels in Plasma in Alzheimer's Disease Compared to Healthy Controls (4) 1223–1230
- Sundström, J., see Sundelöf, J. (4) 1223–1230
- Szalai, A., see Deli, M.A. (3) 777–794
- Tabaton, M., see Borghi, R. (3) 771–775
- Tajes, M., see Ill-Raga, G. (2) 641–652
- Talib, L.L., see Diniz, B.S. (4) 1305–1311
- Tamagno, E., see Borghi, R. (3) 771–775
- Tanzi, R.E., see Lamberta, J.-C. (1) 247–255
- Tanzi, R.E., see Zhang, C. (2) 683–694
- Taylor, H., T. Fraser, J.S. Miners, P.G. Kehoe and S. Love, Oxidative Balance in Alzheimer's Disease: Relationship to APOE, Braak Tangle Stage, and the Concentrations of Soluble and Insoluble Amyloid- $\beta$  (4) 1363–1373
- Teipel, S.J., see Förster, S. (2) 581–591
- Teipel, S.J., T. Meindl, M. Wagner, B. Stieltjes, S. Reuter, K.-H. Hauenstein, M. Filippi, U. Ernemann, M.F. Reiser and H. Hampel, Longitudinal Changes in Fiber Tract Integrity in Healthy Aging and Mild Cognitive Impairment: A DTI Follow-Up Study (2) 507–522
- Teixeira, A.L., see Diniz, B.S. (4) 1305–1311
- Teplow, D.B., see Wang, J. (2) 653–661
- Teramukai, S., see Zhou, B. (2) 673–682
- Thambisetty, M., R. Tripaldi, J. Riddoch-Contreras, A. Hye, Y. An, J. Campbell, J. Sojkova, A. Kinsey, S. Lynham, Y. Zhou, L. Ferrucci, D.F. Wong, S. Lovestone and S.M. Resnick, Proteome-Based Plasma Markers of Brain Amyloid- $\beta$  Deposition in Non-Demented Older Individuals (4) 1099–1109
- Thompson, P.M., see Prestia, A. (4) 1339–1349
- Tierney, M.C., R. Moineddin and I. McDowell, Prediction of All-Cause Dementia Using Neuropsychological Tests within 10 and 5 Years of Diagnosis in a Community-Based Sample (4) 1231–1240
- Tierney, M.C., R. Moineddin, A. Morra, J. Manson and J. Blake, Intensity of Recreational Physical Activity throughout Life and Later Life Cognitive Functioning in Women (4) 1331–1338
- Timmer, N.M., H.B. Kuiperij, R.M.W. de Waal and M.M. Verbeek, Do Amyloid- $\beta$ -associated Factors Co-deposit with A $\beta$  in Mouse Models for Alzheimer's Disease? (2) 345–355

- Titi, L., see Bilotta, F. (S3) S81–S89
- Tognoni, G., see Lamberta, J.-C. (1) 247–255
- Tokita, Y., K. Kaji, J. Lu, Y. Okura, K. Kohyama and Y. Matsumoto, Assessment of Non-Viral Amyloid- $\beta$  DNA Vaccines on Amyloid- $\beta$  Reduction and Safety in Rhesus Monkeys (4) 1351–1361
- Tóth, A., see Deli, M.A. (3) 777–794
- Townsend, K., see Chen, S. (4) 1313–1329
- Trincado, R., see Bermejo-Pareja, F. (3) 949–958
- Tripaldi, R., see Thambisetty, M. (4) 1099–1109
- Tripathi, M. and D. Vibha, Unusual Risk Factors for Cognitive Decline (S3) S57–S65
- Tsolaki, M., see Paajanen, T. (4) 1089–1097
- Tumani, H., see Steinacker, P. (1) 119–128
- Tunnard, C., see Paajanen, T. (4) 1089–1097
- Turner, A.J., see Whitehouse, I.J. (3) 1023–1031
- Tzimopoulou, S., V.J. Cunningham, T.E. Nichols, G. Searle, N.P. Bird, P. Mistry, I.J. Dixon, W.A. Hallett, B. Whitcher, A.P. Brown, M. Zvartau-Hind, N. Lotay, R.Y.K. Lai, M. Castiglia, B. Jeter, J.C. Matthews, K. Chen, D. Bandy, E.M. Reiman, M. Gold, E.A. Rabiner and P.M. Matthews, A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying [ $^{18}$ F]FDG-PET for Evaluation of Metabolic Therapy with Rosiglitazone XR in Mild to Moderate Alzheimer's Disease (4) 1241–1256
- Tzourio, C., see Lamberta, J.-C. (1) 247–255
- Tzourio, C., see Zhu, Y.-C. (2) 663–672
- Vaitl, A., see Förster, S. (2) 581–591
- Valdivieso, F., see Lamberta, J.-C. (1) 247–255
- Valdivieso, F., see Martínez-García, A. (4) 1181–1187
- Valla, J., R. Yaari, A.B. Wolf, Y. Kusne, T.G. Beach, A.E. Roher, J.J. Corneveaux, M.J. Huentelman, R.J. Caselli and E.M. Reiman, Reduced Posterior Cingulate Mitochondrial Activity in Expired Young Adult Carriers of the *APOE*  $\epsilon$ 4 Allele, the Major Late-Onset Alzheimer's Susceptibility Gene (1) 307–313
- Van Broeckhoven, C., see Lamberta, J.-C. (1) 247–255
- van de Berg, W.D.J., see Reesink, F.E. (1) 87–95
- van de Berg, W.D.J., see Richard, E. (3) 811–818
- van der Flier, W.M., see Mulder, S.D. (4) 1073–1079
- van der Flier, W.M., see Reesink, F.E. (1) 87–95
- Van der Linden, M., see Collette, F. (3) 897–907
- van Dijk, K.D., see Reesink, F.E. (1) 87–95
- van Gool, W.A., see Richard, E. (3) 811–818
- van Haastert, E.S., see Richard, E. (3) 811–818
- Vandenbark, A.A., see Subramanian, S. (2) 619–629
- Vanderweyde, T., M.M. Bednar, S.A. Forman and B. Wolozin, Iatrogenic Risk Factors for Alzheimer's Disease: Surgery and Anesthesia (S3) S91–S104
- Vargas, T., see Martínez-García, A. (4) 1181–1187
- Vecchio, F., see Babiloni, C. (4) 1047–1064
- Veerhuis, R., see Mulder, S.D. (4) 1073–1079
- Vega, S., see Benito-León, J. (1) 159–170
- Vellas, B., see Dangour, A.D. (1) 205–224
- Vellas, B., see Paajanen, T. (4) 1089–1097
- Vendemiale, G., see Frisardi, V. (3) 715–740
- Vepsäläinen, S., see Lamberta, J.-C. (1) 247–255
- Verbeek, M.M., see Reesink, F.E. (1) 87–95
- Verbeek, M.M., see Timmer, N.M. (2) 345–355
- Veszélka, S., see Deli, M.A. (3) 777–794
- Viana, R.J.S., R.M. Ramalho, A.F. Nunes, C.J. Steer and C.M.P. Rodrigues, Modulation of Amyloid- $\beta$  Peptide-Induced Toxicity through Inhibition of JNK Nuclear Localization and Caspase-2 Activation (2) 557–568
- Vibha, D., see Tripathi, M. (S3) S57–S65
- Vicente-Villardón, J.L., see Cacho, J. (3) 889–896
- Vilalta-Franch, J., see Garre-Olmo, J. (4) 1157–1167
- Vilalta-Franch, J., see Garre-Olmo, J. (4) 1169–1180
- Vilarrasa, A.B., see Garre-Olmo, J. (4) 1157–1167
- Vilarrasa, A.B., see Garre-Olmo, J. (4) 1169–1180
- Vilella, E., see Martínez-García, A. (4) 1181–1187
- Villarejo, A., see Bermejo-Pareja, F. (3) 949–958
- Villarreal, J., see Liu, D. (2) 443–457
- Villemagne, V.L., see Bahar-Fuchs, A. (4) 1081–1087
- Vincent, A.J., R. Gasperini, L. Foa and D.H. Small, Astrocytes in Alzheimer's Disease: Emerging Roles in Calcium Dysregulation and Synaptic Plasticity (3) 699–714
- Virta, J.J., T. Järvenpää, K. Heikkilä, M. Perola, M. Koskenvuo, I. Räihä, J.O. Rinne and J. Kaprio, Midlife Alcohol Consumption and Later Risk of Cognitive Impairment: A Twin Follow-up Study (3) 939–948
- Wadsworth, T.L., see Subramanian, S. (2) 619–629
- Wagener, J.F., see Chen, X. (4) 1289–1303
- Wahlund, L.-O., see Westman, E. (1) 171–181
- Walach, H., see Mutter, J. (2) 357–374
- Wang, B.-J., see Kapoor, A. (2) 423–442
- Wang, J., I. Santa-Maria, L. Ho, H. Ksiezak-Reding, K. Ono, D.B. Teplow and G.M. Pasinetti, Grape Derived Polyphenols Attenuate Tau Neuropathology in a Mouse Model of Alzheimer's Disease (2) 653–661
- Wang, L., see Yang, S.-G. (1) 107–117
- Wang, X., see Liu, J. (2) 541–556
- Wang, X., see Murphy, M.P. (1) 135–150
- Watson, G.S., see Baker, L.D. (2) 569–579
- Wegiel, J., see Ji, L. (2) 609–617

- Weidner, A., see Murphy, M.P. (1) 135–150  
 Weidner, A.M., see Ebenezer, P.J. (3) 839–848  
 Westman, E., L.-O. Wahlund, C. Foy, M. Poppe, A. Cooper, D. Murphy, C. Spenger, S. Lovestone and A. Simmons, Combining MRI and MRS to Distinguish Between Alzheimer's Disease and Healthy Controls (1) 171–181  
 Whitcher, B., see Tzimopoulou, S. (4) 1241–1256  
 Whitehouse, I.J., C. Jackson, A.J. Turner and N.M. Hooper, Prion Protein is Reduced in Aging and in Sporadic but not in Familial Alzheimer's Disease (3) 1023–1031  
 Whitehouse, P.J., see Dangour, A.D. (1) 205–224  
 Wilkinson, C.W., see Baker, L.D. (2) 569–579  
 Wiltfang, J., see Steinacker, P. (1) 119–128  
 Winblad, B., E. Giacobini, L. Frölich, L.T. Friedhoff, G. Bruinsma, R.E. Becker and N.H. Greig, Phenserine Efficacy in Alzheimer's Disease (4) 1201–1208  
 Winblad, B., see Gil-Bea, F.J. (2) 405–413  
 Winblad, B., see Gil-Bea, F.J. (3) 829–838  
 Wojciak-Stothard, B., see Lichtenstein, M.P. (4) 1135–1155  
 Wolf, A.B., see Valla, J. (1) 307–313  
 Wolfe, M., see Lu, Q. (1) 235–245  
 Wolozin, B., see Vanderweyde, T. (S3) S91–S104  
 Wong, D.F., see Thambisetty, M. (4) 1099–1109  
 Wszolek, Z., see Gabryelewicz, T. (4) 1123–1133  
 Wu, G.-H., see Kapoor, A. (2) 423–442  
 Wu, J., see Yang, J. (1) 225–234  
 Wu, Y., see Liu, J. (2) 541–556  
 Wu, J., see Ginsberg, S.D. (2) 631–639  
  
 Xia, W., see Lu, Q. (1) 235–245  
 Xiao, Y., see Cao, Y. (1) 329–342  
 Xie, Z., see Zhang, C. (2) 683–694  
 Xue, D., see Yang, S.-G. (1) 107–117  
  
 Yaari, R., see Sabbagh, M.N. (3) 1015–1021  
 Yaari, R., see Valla, J. (1) 307–313  
 Yakushev, I., see Förster, S. (2) 581–591  
 Yan, X.-X., see Struble, R.G. (2) 393–399  
 Yang, J., T. Ogasa, Y. Ohta, K. Abe and J. Wu, Decline of Human Tactile Angle Discrimination in Patients with Mild Cognitive Impairment and Alzheimer's Disease (1) 225–234  
 Yang, Q., see Yu, C.-J. (1) 257–266  
 Yang, S.-G., X. Zhang, X.-S. Sun, T.-J. Ling, Y. Feng, X.-Y. Du, M. Zhao, Y. Yang, D. Xue, L. Wang and R.-T. Liu, Diverse Ecdysterones Show Different Effects on Amyloid- $\beta_{42}$  Aggregation but All Uniformly Inhibit Amyloid- $\beta_{42}$ -Induced Cytotoxicity (1) 107–117  
 Yang, Y., see Yang, S.-G. (1) 107–117  
 Yen, C.-T., see Kapoor, A. (2) 423–442  
 Yew, D.T., see Liu, J. (2) 541–556  
 Yoshiyama, Y., A. Kojima, C. Ishikawa and K. Arai, Anti-Inflammatory Action of Donepezil Ameliorates Tau Pathology, Synaptic Loss, and Neurodegeneration in a Tauopathy Mouse Model (1) 295–306  
 Yu, C.-J., M.-F. Zheng, C.-X. Kuang, W.-D. Huang and Q. Yang, Oren-Gedoku-to and Its Constituents with Therapeutic Potential in Alzheimer's Disease Inhibit Indoleamine 2, 3-Dioxygenase Activity *In Vitro* (1) 257–266  
  
 Zekanowski, C., see Gabryelewicz, T. (4) 1123–1133  
 Zelenika, D., see Lamberta, J.-C. (1) 247–255  
 Zetterberg, H., see Chiasserini, D. (4) 1281–1288  
 Zhang, C., A. Browne, J.R. DiVito, J.A. Stevenson, D. Romano, Y. Dong, Z. Xie and R.E. Tanzi, Amyloid- $\beta$  Production Via Cleavage of Amyloid- $\beta$  Protein Precursor is Modulated by Cell Density (2) 683–694  
 Zhang, L., see Ebenezer, P.J. (3) 839–848  
 Zhang, X., see Yang, S.-G. (1) 107–117  
 Zhao, M., see Yang, S.-G. (1) 107–117  
 Zhao, Q., see Zhou, B. (2) 673–682  
 Zheng, M.-F., see Yu, C.-J. (1) 257–266  
 Zhou, B., Q. Zhao, S. Teramukai, D. Ding, Q. Guo, M. Fukushima and Z. Hong, Executive Function Predicts Survival in Alzheimer Disease: A Study in Shanghai (2) 673–682  
 Zhou, Y., see Thambisetty, M. (4) 1099–1109  
 Zhu, Y.-C., C. Dufouil, A. Soumaré, B. Mazoyer, H. Chabriat and C. Tzourio, High Degree of Dilated Virchow-Robin Spaces on MRI is Associated with Increased Risk of Dementia (2) 663–672  
 Zimmer, D., see Ellis, G. (2) 593–607  
 Zvartau-Hind, M., see Tzimopoulou, S. (4) 1241–1256